Table 1.

Characteristics of studied subjects and their samples.

	Crohn’s disease [n = 54]			Juvenile idiopathic arthritis [n = 18]			Healthy control [n = 49]
Status	Total	Received anti-TNF	Without anti-TNF	Total	Received anti-TNF	Without anti-TNF
No. of subjects	54	37	17	18	14	4	49
Age at diagnosis, median in years [IQR]	12.6 [9.2–15.0]	12.9 [9.1–15.0]	12.5 [10.2–14.9]	8.6 [3.8–10.7]	8.6 [3.8–10.8]	8.8 [6.8–10.0]	–
Female sex, n [%]	22 [41%]	15 [41%]	7 [41%]	11	9 [64%]	2 [50%]	20 [41%]
Caucasian ethnicity, n [%]	52 [96%]	35 [95%]	17 [100%]	18	14 [100%]	4 [100%]	49
Family history of IBD, n [%]	11 [20%]	9 [24%]	2 [12%]	–	–	–	–
No. of samples per patient, median [IQR]	6.0 [5.0–8.0]	6.0 [5.0–8.0]	6.0 [3.0–9.0]	6.0 [4.0–6.75]	6.0 [5.0–6.75]	4.0 [3.75–5.75]	1.0 [1.0–1.0]
Faecal calprotectin concentration [µg/g]; median [IQR] of patient means	1158 [219–1862]	1424 [655–1988]	219 [52–1807]	20 [10–55]	24 [10–56]	11 [6.4–16]	11 [7–21]
Treatment regimes a
Immunomodulator monotherapy [azathioprine/methotrexate]	13 [24%]	–	13 [76%]	3 [17%]	–	3 [75%]	–
Anti-TNFα monotherapyb	19 [35%]	19 [51%]	–	4 [22%]	4 [29%]	–	–
Combined immunomodulatory + anti-TNFα	18 [33%]	18 [49%]	–	10 [56%]	10 [71%]	–	–
Other treatmentc	4 [7%]	–	4 [24%]	1 [6%]	–	1 [25%]

^aDistribution of immunomodulatory agents: in CD 31/54 [57%] were treated with immunomodulatory agents [azathioprine 25, methotrexate 6]; in JIA 13/18 [72%] were immunomodulatory agents [all methotrexate].

^bDistribution of anti-TNF agents in CD: infliximab 18/37 [49%]; adalimumab 19/37 [51%]; in JIA, all subjects received adalimumab as anti-TNF.

^cIn CD, three out of the four subjects provided samples only before the diagnosis and any treatment of CD; one subject was treated without immunomodulatory agents with supplementary enteral nutrition only; in JIA, this one patient was treated with non-steroid anti-inflammatory drugs only.

IQR = interquartile range.